Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel P Hermans

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Current Cardiology Reviews|May 3, 2011
Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELDMichel P Hermans
Diabetes & Vascular Disease Research|May 18, 2011
Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORDMichel P Hermans
Acta Clinica Belgica|January 1, 2019
"Mind the gap please…": estimated vs. measured A<sub>1</sub>c from continuous measurement of interstitial glucose over a 3-month period in patients with type 1 diabetesPhilippe Oriot, Michel P Hermans
Journal of Diabetes and Its Complications|January 5, 2023
Intermittent-scanned continuous glucose monitoring with low glucose alarms decreases hypoglycemia incidence in middle-aged adults with type 1 diabetes in real-life settingPhilippe Oriot, Michel P Hermans
Acta Clinica Belgica|June 17, 2020
Euglycemic diabetic ketoacidosis in a patient with type 1 diabetes and SARS-CoV-2 pneumonia: case-report and review of the literaturePhilippe Oriot, Michel P Hermans
Acta Clinica Belgica|July 7, 2017
Prevalence and co-prevalence of comorbidities in Belgian patients with type 2 diabetes mellitus: a transversal, descriptive studyMichel P Hermans, Nicolas Dath
Current Opinion in Endocrinology, Diabetes, and Obesity|March 2, 2018
Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetesMichel P Hermans, Paul Valensi
Therapeutic Advances in Chronic Disease|December 20, 2012
Reducing vascular events risk in patients with dyslipidaemia: an update for cliniciansMichel P Hermans, Jean-Charles Fruchart
Acta Clinica Belgica|May 7, 2016
Can an electronic glycaemic notebook associated with an insulin calculator improve HbA1c in diabetic patients on a multiple insulin injections regimen? A 26-week observational real-life studyPhilippe Oriot, Michel Ponchon, Michel P Hermans
Journal of Clinical Lipidology|September 27, 2012
Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levelsLaurent Querton, Martin Buysschaert, Michel P Hermans
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Current Cardiology Reviews|May 3, 2011
Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELDMichel P Hermans
Diabetes & Vascular Disease Research|May 18, 2011
Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORDMichel P Hermans
Acta Clinica Belgica|January 1, 2019
"Mind the gap please…": estimated vs. measured A<sub>1</sub>c from continuous measurement of interstitial glucose over a 3-month period in patients with type 1 diabetesPhilippe Oriot, Michel P Hermans
Journal of Diabetes and Its Complications|January 5, 2023
Intermittent-scanned continuous glucose monitoring with low glucose alarms decreases hypoglycemia incidence in middle-aged adults with type 1 diabetes in real-life settingPhilippe Oriot, Michel P Hermans
Acta Clinica Belgica|June 17, 2020
Euglycemic diabetic ketoacidosis in a patient with type 1 diabetes and SARS-CoV-2 pneumonia: case-report and review of the literaturePhilippe Oriot, Michel P Hermans
Acta Clinica Belgica|July 7, 2017
Prevalence and co-prevalence of comorbidities in Belgian patients with type 2 diabetes mellitus: a transversal, descriptive studyMichel P Hermans, Nicolas Dath
Current Opinion in Endocrinology, Diabetes, and Obesity|March 2, 2018
Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetesMichel P Hermans, Paul Valensi
Therapeutic Advances in Chronic Disease|December 20, 2012
Reducing vascular events risk in patients with dyslipidaemia: an update for cliniciansMichel P Hermans, Jean-Charles Fruchart
Acta Clinica Belgica|May 7, 2016
Can an electronic glycaemic notebook associated with an insulin calculator improve HbA1c in diabetic patients on a multiple insulin injections regimen? A 26-week observational real-life studyPhilippe Oriot, Michel Ponchon, Michel P Hermans
Journal of Clinical Lipidology|September 27, 2012
Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levelsLaurent Querton, Martin Buysschaert, Michel P Hermans
Pageof 13